Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 4;10(1):134.
doi: 10.1186/s13045-017-0502-3.

Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis

Ying-Jun Chang  1 , Yu Wang  1 , Yan-Rong Liu  1 , Lan-Ping Xu  1 , Xiao-Hui Zhang  1 , Huan Chen  1 , Yu-Hong Chen  1 , Feng-Rong Wang  1 , Wei Han  1 , Yu-Qian Sun  1 , Chen-Hua Yan  1 , Fei-Fei Tang  1 , Xiao-Dong Mo  1 , Kai-Yan Liu  1 , Xiao-Jun Huang  2   3
Affiliations

Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis

Ying-Jun Chang et al. J Hematol Oncol. .

Abstract

Background: This study compared the effects of pre-transplantation minimal residual disease (pre-MRD) on outcomes in AML patients who underwent human leukocyte antigen-matched sibling donor transplantation (MSDT) or who received unmanipulated haploidentical allografts.

Methods: A retrospective study (n = 339) and a prospective study (n = 340) were performed. MRD was determined using multiparameter flow cytometry.

Results: Either after retrospective or prospective analysis, patients with negative pre-MRD (pre-MRDneg) had a lower incidence of relapse than those with positive pre-MRD (pre-MRDpos) in MSDT settings (P < 0.001 for all), but relapse was comparable in Haplo-SCT settings for patients with pre-MRDneg versus pre-MRDpos (P = 0.866 and 0.161, respectively). In either the retrospective (n = 65) or the prospective study (n = 76), pre-MRDpos subjects receiving Haplo-SCT experienced a lower incidence of relapse than those who underwent MSDT (P < 0.001 and p = 0.017, respectively). Of the patients with pre-MRDpos in either the total (n = 141) or the subgroup excluding cases which received donor lymphocyte infusion (DLI; n = 105), those who underwent MSDT had a higher incidence of relapse than those receiving haplo-SCT (P < 0.01 for all). Multivariate analysis showed that, for pre-MRDpos cases, haplo-SCT was associated with a low incidence of relapse and with better LFS and OS in either retrospective group, prospective group, combination groups, or subgroup not including cases which received DLI.

Conclusions: The results indicated that, for pre-MRD-positive AML patients, haplo-SCT was associated with lower incidence of relapse and better survival, suggesting a stronger anti-leukemia effect.

Keywords: Acute myeloid leukemia; Allogeneic stem cell transplantation; Minimal residual disease; Multiparameter flow cytometry; Unmanipulated haploidentical allografts.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

All of the included subjects provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Peking University.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
CONSORT (the Consolidated Standards of Reporting Trials) diagram
Fig. 2
Fig. 2
Relationship between transplant modality and transplant outcomes for AML patients with pre-transplantation MRD who underwent allo-SCT (n = 141). Kaplan–Meier estimates of (a) cumulative incidence of relapse mortality, (b) cumulative incidence of non-relapse, (c) leukemia-free survival, and (d) overall survival
See this image and copyright information in PMC

References

    1. Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9(10):579–590. doi: 10.1038/nrclinonc.2012.150. - DOI - PubMed
    1. Wang Y, Chang YJ, Xu LP, et al. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood. 2014;124(6):843–850. doi: 10.1182/blood-2014-03-563130. - DOI - PubMed
    1. McCurdy SR, Kanakry JA, Showel MM, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015;125(19):3024–3031. doi: 10.1182/blood-2015-01-623991. - DOI - PMC - PubMed
    1. Wang Y, Liu QF, Xu LP, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015;125(25):3956–3962. doi: 10.1182/blood-2015-02-627786. - DOI - PubMed
    1. Walker I, Panzarella T, Couban S, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 2016;17(2):164–173. doi: 10.1016/S1470-2045(15)00462-3. - DOI - PubMed

Publication types

MeSH terms